Latanoprost Aurobindo

Latanoprost, the active ingredient in Latanoprost Aurobindo, is a prostaglandin F2α analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is employed in the management of glaucoma and ocular hypertension in adult patients.

GNH USA supplies Latanoprost Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance. The company provides reliable logistics and documentation for cross‑border procurement.

Latanoprost is a prostaglandin analog used to reduce intra‑ocular pressure in several glaucoma‑related conditions.

- Primary open‑angle glaucoma: lowers intra‑ocular pressure to slow disease progression. - Ocular hypertension: reduces elevated eye pressure to prevent conversion to glaucoma. - Secondary open‑angle glaucoma: helps control pressure when caused by other ocular conditions.

Latanoprost may cause ocular and systemic reactions, most of which are mild and reversible.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Increased eyelash growth: longer, thicker lashes. - Iris pigmentation: gradual darkening of the iris. - Eye irritation: transient burning or stinging. - Blurred vision: temporary visual disturbance.

Serious or Rare Side Effects: - Severe eye inflammation: uveitis or iritis requiring medical attention. - Allergic reaction: swelling, rash, or severe itching. - Vision changes: sudden loss of vision or visual field defects. - Ocular infection: increased risk if sterility is compromised. - Corneal edema: swelling of the cornea affecting clarity.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for adverse events.

- Monitor intra‑ocular pressure: schedule regular measurements to assess efficacy. - Assess for ocular infections: avoid use if active infection is present. - Caution in corneal disease: may exacerbate existing corneal pathology. - Discontinue before ocular surgery: stop treatment as advised by the surgeon. - Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost can interact with other ophthalmic agents, potentially altering efficacy or safety.

Major Interactions (Avoid): - Concurrent prostaglandin analogs: additive ocular side effects. - Beta‑blocker eye drops: may diminish overall pressure‑lowering effect. - Systemic carbonic anhydrase inhibitors: risk of excessive IOP reduction.

Moderate Interactions (Monitor Closely): - Topical corticosteroids: may reduce Latanoprost efficacy. - Non‑steroidal anti‑inflammatory eye drops: possible irritation. - Systemic NSAIDs: generally safe but monitor for any unexpected ocular response.